William F. Keane

Q: What Schools Are Affiliated With William F. Keane

William F. Keane is affiliated with the following schools: Aarhus University, University of Minnesota

William F. Keane's AcademicInfluence.com Rankings

William F. Keane

Philosophy

#6807

World Rank

#9910

Historical Rank

Logic

#3913

World Rank

#5141

Historical Rank

philosophy Degrees

Download Badge

Philosophy

William F. Keane's Degrees

Doctorate Medicine University of California, San Francisco

Why Is William F. Keane Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William F. Keane's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

K/DOQI clinical practice guidelines for chronic kidney disease (2002) (8858)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. (2001) (5071)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. (2004) (956)
Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy (2004) (746)
Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. (1984) (702)
Nephropathy in diabetes. (2004) (698)
Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis (1993) (622)
Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. (1999) (596)
Prevention of diabetic renal disease with special reference to microalbuminuria (1995) (567)
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. (1989) (547)
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. (2003) (517)
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. (1988) (428)
Adult Peritoneal Dialysis-Related Peritonitis Treatment Recommendations: 2000 Update (2000) (426)
Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. (2000) (341)
Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. (1995) (330)
Pharmacokinetics of vancomycin in patients with various degrees of renal function (1984) (327)
Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. (1996) (324)
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. (2007) (305)
Pharmacologic Treatment of Hyperlipidemia Reduces Glomerular Injury in Rat 5/6 Nephrectomy Model of Chronic Renal Failure (1988) (294)
Renal injury of diet-induced hypercholesterolemia in rats. (1990) (280)
The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. (1992) (271)
Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). (2003) (260)
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. (2001) (260)
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. (2004) (221)
Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. (1988) (220)
Effects of genetic obesity on renal structure and function in the Zucker rat. (1985) (220)
Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. (1997) (204)
Lipids and the kidney. (1994) (201)
Lovastatin inhibits proliferation of rat mesangial cells. (1993) (182)
Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. (1987) (179)
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. (2006) (179)
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? (1996) (178)
Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. (1985) (175)
Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. (1989) (165)
Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. (2005) (163)
Proteinuria: its clinical importance and role in progressive renal disease. (2000) (159)
Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. (1981) (158)
Glomerular hemodynamic and structural alterations in experimental diabetes mellitus (1988) (158)
Recent advances in statins and the kidney. (1999) (156)
Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis. (1993) (143)
The assessment of risk factors in 462 patients with acute renal failure. (1985) (142)
The role of lipids in renal disease: future challenges. (2000) (141)
Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis. (1983) (141)
INCIDENCE AND TYPE OF INFECTIONS OCCURRING IN 445 CHRONIC HEMODIALYSIS PATIENTS (1977) (138)
The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) (2000) (135)
Glomerular mesangium: its function and relationship to angiotensin II. (1985) (134)
Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. (1994) (133)
Hyperlipidemia and progressive renal disease. (1991) (132)
Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. (1987) (128)
Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis. (1984) (126)
Reviews and Original Articles (1996) (125)
Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. (1987) (122)
Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. (1985) (112)
Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. (1992) (104)
Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. (2001) (102)
Lovastatin retards the progression of established glomerular disease in obese Zucker rats. (1993) (102)
Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. (1998) (97)
Radiation-induced renal disease. A clinicopathologic study. (1976) (97)
Mechanism of Escherichia coli alpha-hemolysin-induced injury to isolated renal tubular cells. (1987) (95)
Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. (1984) (95)
Protective Effect of HMG-CoA Reductase Inhibitor on Experimental Renal Ischemia-Reperfusion Injury (2002) (92)
Relationship among altered glomerular barrier permselectivity, angiotensin II, and mesangial uptake of macromolecules. (1985) (92)
Early glomerular changes in rats with dietary-induced hypercholesterolemia. (1995) (91)
Hyperlipidemia and the progression of renal disease. (1988) (90)
Lipids and the kidney. (1990) (88)
Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids (1984) (87)
Determinants of glomerular filtration and plasma flow in experimental diabetic rats. (1981) (87)
Role of hypertension in progressive glomerular immune injury. (1985) (87)
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. (2003) (86)
Disposition of Gabapentin in Anuric Subjects on Hemodialysis (1995) (85)
Correlation of office and ambulatory blood pressure measurements with urinary albumin and N-acetyl-beta-D-glucosaminidase excretions in essential hypertension. (1988) (85)
Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. (2013) (84)
Lipid abnormalities in end stage renal disease. (1998) (80)
Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril. (1992) (80)
Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. (1989) (80)
Treatment Recommendations 1993 Update (1993) (80)
Consensus Development Conference on the Diagnosis and Management of Nephropathy in Patients with Diabetes Mellitus (1994) (78)
Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program. (2003) (78)
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. (2003) (76)
Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. (2000) (75)
Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. (1995) (74)
Adriamycin-induced chronic proteinuria: a structural and functional study. (1985) (70)
Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. (2001) (70)
Oxidative modification of low-density lipoproteins by mesangial cells. (1993) (68)
Lipids and progressive renal injury. (1989) (67)
Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. (1996) (64)
The central role of nuclear factor-κB in mesangial cell activation (1999) (60)
Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. (1992) (60)
The pharmacokinetics of losartan in renal insufficiency (1995) (59)
Antimicrobial Treatment of Peritonitis Associated with Continuous Ambulatory Peritoneal Dialysis (1991) (57)
The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. (1990) (56)
The renin-angiotensin system in the type II diabetic obese Zucker rat. (1993) (56)
Proteinuria and cardiovascular disease. (2001) (54)
CAPD Related Peritonitis Management and Antibiotic Therapy Recommendations Travenol Peritonitis Management Advisory Committee (1987) (53)
Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages (1985) (52)
Effects of Nephron Loss on Glomerular Hemodynamics and Morphology in Diabetic Rats (1986) (51)
Lipophilic statins induce apoptosis of human vascular smooth muscle cells. (1999) (50)
Perinephric abscess in patients with polycystic kidney disease undergoing chronic hemodialysis. (1979) (49)
Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis Treatment Recommendations: 1989 Update (1989) (48)
Irreversible acute renal failure in idiopathic nephrotic syndrome. (1976) (46)
Hypertension, hyperlipidemia, and renal damage. (1993) (44)
Effects of cyclosporine on the isolated perfused rat kidney. (1987) (44)
Cholesterol-Lowering Effects oHypercholesterolemiain Patients With Mild to Moderate Hypercholesterolemia (1992) (44)
Human peritoneal macrophage phagocytic, killing, and chemiluminescent responses to opsonized Listeria monocytogenes (1983) (43)
Experimental pyelonephritis. XIV. Pyelonephritis in normal mice produced by inoculation of E. coli into the bladder lumen during water diuresis. (1967) (42)
Lipids in progression of renal disease. (1997) (42)
Survival and rehabilitation of patients on home hemodialysis. Five years' experience. (1973) (41)
Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. (1985) (41)
Lipid-lnduced Glomerular Injury (1994) (41)
Age is a determinant of the glomerular morphologic and functional responses to chronic nephron loss. (1985) (40)
The role of altered lipid metabolism in the progression of renal disease: experimental evidence. (1991) (40)
Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? (1992) (40)
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. (2005) (39)
Impact of dietary fatty acid supplementation on renal injury in obese Zucker rats. (1991) (38)
Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. (1996) (37)
Unilateral Shwartzman reaction: cortical necrosis in one kidney following in vivo perfusion with endotoxin. (1977) (36)
Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency. (1988) (36)
Glomerular permeability to neutral and anionic dextrans in experimental diabetes. (1982) (35)
Glomerular hemodynamic and structural correlations in long-term experimental diabetic rats. (1984) (35)
Host Defense Mechanisms of the Peritoneal Cavity and Continuous Ambulatory Peritoneal Dialysis (1984) (34)
Enhancement of endotoxin-induced isolated renal tubular cell injury by toxic shock syndrome toxin 1. (1986) (34)
Host Defenses and Infectious Complications in Maintenance Hemodialysis Patients (1996) (33)
Hyperlipidemia in the nephrotic syndrome. (1990) (33)
Mesangial function in ureteral obstruction in the rat. Blockade of the efferent limb. (1979) (32)
Polyamino acid enhancement of bacterial phagocytosis by human polymorphonuclear leukocytes and peritoneal macrophages (1984) (32)
Intravascular and extracellular volumes in the diabetic rat. (1981) (30)
The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis. (1995) (30)
Beta-endorphin stimulates human polymorphonuclear leukocyte superoxide production via a stereoselective opiate receptor. (1987) (30)
Intestinal and Hepatic Cholesterol Synthesis in the Alloxan Diabetic Rat 1 (1982) (30)
Intracellular survival of Candida albicans in peritoneal macrophages from chronic peritoneal dialysis patients. (1986) (30)
Lipid abnormalities in patients with chronic kidney disease. (2011) (30)
Diabetic nephropathy. (2003) (30)
Renal protective effects of angiotensin-converting enzyme inhibition. (1990) (30)
The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats. (1995) (28)
The mevalonate pathway: importance in mesangial cell biology and glomerular disease. (1993) (28)
Cefotaxime and desacetyl cefotaxime kinetics in renal impairment (1985) (28)
Hemodialysis elimination rates and clearance of gentamicin and tobramycin (1984) (28)
The central role of nuclear factor-kappa B in mesangial cell activation. (1999) (27)
Successful renal transplantation in progressive systemic sclerosis. (1976) (27)
Immunosuppressive effects of leflunomide in experimental chronic vascular rejection. (1995) (26)
The national epidemic of chronic kidney disease (2001) (26)
Lipids and progressive renal failure. (1996) (26)
Metabolic pathogenesis of cardiorenal disease. (2001) (26)
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study (2006) (26)
Continuous ambulatory peritoneal dialysis (CAPD) peritonitis treatment recommendations: 1989 update. The Ad Hoc Advisory Committee on Peritonitis Management. (1989) (25)
Disposition of Famotidine in Renal Insufficiency (1987) (25)
Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease (2000) (25)
Impaired mesangial clearance of macromolecules in rats with chronic mesangial ferritin-antiferritin immune complex deposition. (1980) (25)
High protein intake accelerates glomerulosclerosis independent of effects on glomerular hemodynamics. (1990) (24)
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies (2007) (24)
Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. (1997) (24)
Lipids and the progression of renal disease. (1990) (23)
Risk factors for glomerular injury in rats with genetic hypertension. (1989) (23)
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. (2001) (23)
Recommendations for reducing the high morbidity and mortality of United States maintenance dialysis patients. The National Kidney Foundation. (1994) (22)
Therapeutic implications of lipid-lowering agents in the progression of renal disease. (1989) (22)
The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with esrd. (2001) (22)
Assessment of structure and function in progressive renal disease. (1997) (22)
Lipids and progressive renal disease: the cardio-renal link. (1999) (22)
The role of lipid abnormalities in the pathogenesis of chronic, progressive renal disease. (1991) (20)
Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-1-infected monocytes. (1998) (20)
The Future of Clinical Trials in Chronic Renal Disease: Outcome of an NIH/FDA/Physician Specialist Conference (2000) (20)
Modulatory effects of β-endorphin on interferon-γ production by cultured peripheral blood mononuclear cells: Heterogeneity among donors and the influence of culture medium (1988) (20)
Opsonization of Legionella pneumophila in human serum: key roles for specific antibodies and the classical complement pathway. (1985) (19)
The obese Zucker rat model of glomerular injury in type II diabetes. (1987) (19)
Host Defense Mechanisms of the Peritoneal Cavity and Continuous Ambulatory Peritoneal Dialysis (1991) (19)
Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis. (1999) (19)
Mononuclear phagocytic system stimulation. Protective role from glomerular immune complex deposition. (1981) (19)
Adjunctive therapy with intravenous human immunoglobulin G improves survival of patients with acute renal failure. (1991) (18)
Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study. (2005) (18)
Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency (1991) (17)
Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure (1993) (17)
The effect of famotidine on renal function in patients with renal insufficiency. (1987) (16)
Pharmacokinetics of Zileuton and Its Metabolites in Patients with Renal Impairment (1997) (16)
Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis. (1994) (15)
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. (2004) (15)
Diabetes in the elderly population. (2000) (14)
Kidney disease and cardiovascular disease: implications of dyslipidemia. (2005) (14)
Pharmacokinetics of Tazobactam M1 Metabolite After Administration of Piperacillin/Tazobactam in Subjects with Renal Impairment (1994) (14)
Renal disease in cryoglobulinemia type II: response to therapy. A case report and review of the literature. (1982) (13)
Determinants of glomerular mesangial localization of immune complexes. Role of endothelial fenestrae. (1981) (13)
Treatment of hyperlipidemia in chronic progressive renal disease. (1993) (13)
Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines. (1997) (13)
The role of lipids in progressive glomerular disease. (1987) (13)
Antihypertensive Therapy with Once‐daily Administration of Terazosin, a New Alpha1‐adrenergic‐receptor Blocker (1985) (13)
Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables. (2017) (12)
Isoprenoids and Ras: potential role in chronic rejection. (1995) (12)
Glomerular hemodynamic effects of dietary polyunsaturated fatty acid supplementation. (1991) (12)
Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing (1989) (12)
Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain. (1988) (12)
Pathogenesis of Atherosclerosis (1964) (11)
Higher haematocrit levels: do they improve patient outcomes, and are they cost effective? (1998) (11)
Effects of carbohydrate restriction on renal injury in the obese Zucker rat. (1986) (10)
Effect of long-term clofibric acid treatment on serum and tissue lipid and cholesterol levels in obese Zucker rats. (1987) (9)
Human peritoneal macrophage cytotoxicity mediated by cytophilic IgG. (1983) (9)
Losartan: lessons learned from the RENAAL study (2006) (9)
Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. (1999) (9)
Lipid-induced glomerular injury. (1994) (9)
Alterations in glomerular proteoglycan metabolism in experimental non-insulin dependent diabetes mellitus. (1993) (9)
The effects of chronic mesangial immune injury on glomerular function. (1980) (9)
Risk factors for nephropathy and cardiovascular disease in diabetic Northern Minnesota American Indians. (1996) (9)
Cefsulodin pharmacokinetics in patients with various degrees of renal function (1983) (8)
Regulation of mesangial cell proliferation by the mevalonate pathway. (1997) (8)
Renal effects of angiotensin II: modulation by calcium and cyclooxygenase products. (1986) (8)
The long-term tolerability of enalapril in hypertensive patients with renal impairment. (1997) (7)
Lipids, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, and progression of renal failure. (1997) (7)
Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30MGKG−1 (1992) (7)
The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy (2012) (7)
Acute glomerulonephritis. A clinical overview. (1984) (7)
Fish oil diet decreases prostacyclin and increases resistance in isolated rat kidneys. (1989) (6)
Effects of immunosuppressive agents, cyclosporin A, FK-506 and genistein on the sysnthesis of 5-lipoxygenase metabolite(s) of arachidonic acid by human mononuclear cells (1992) (6)
Role of lipid peroxidation in the inhibition of mononuclear cell proliferation by normal lipoproteins. (1991) (6)
Derangement of lipid metabolism and its management in renal transplant patients. (1997) (6)
Host Defense Mechanisms in Chronic Ambulatory Peritoneal Dialysis—Associated Peritonitis (1989) (6)
Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease (1992) (6)
Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists: lessons from recent trials (2002) (5)
Pharmacokinetics of MAT9001, an Omega‐3 Fatty Acid Medication, Compared with Eicosapentaenoic Acid Ethyl Esters in Hypertriglyceridemic Subjects (2016) (5)
Infectious Complications in Maintenance Dialysis Patients (1979) (5)
Angiotensin-Converting Enzyme Inhibitors in Chronic Renal Failure (2012) (4)
Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy. (1987) (4)
Causes, Consequences, and Treatment of Hyperlipidemia in Patients with Renal Disease (1990) (4)
Lack of pharmacodynamic interaction between pentoxifylline and warfarin in the rat. (1986) (4)
Mild hypothermia gives better functional preservation than cold or normothermic perfusion of rat kidneys. (1990) (4)
Effect of lipids on glomerular injury and progression of renal disease. (1994) (4)
Renal injury in obese Zucker rats (1992) (3)
Renal diagnostic testing: past, present and future. (1996) (3)
A Large Step in the Treatment of Peritonitis in Peritoneal Dialysis Patients (1996) (3)
Progression of renal disease (1994) (3)
Degenerative and age-related changes in the x-irradiated kidney of the rat. (1978) (3)
Hypertension adverse experiences among osteoarthritis patients treated with rofecoxib, celecoxib, or acetaminophen in the VACT trials (2003) (2)
Modulatory effects of beta-endorphin on interferon-gamma production by cultured peripheral blood mononuclear cells: heterogeneity among donors and the influence of culture medium. (1988) (2)
Chronic renal allograft failure (1995) (2)
Treatment of Peritonitis: Update or New Course (2000) (2)
Glomerular, mesangial and tubular function in mercury chloride (HgCl2) acute renal failure (ARF) (1977) (2)
Isoprenoids, Ras and proliferative glomerular disease. (1997) (2)
Experimental pyelonephritis in the mouse (1968) (1)
Analytical specificity of commercially available methods for serum phenytoin determination. (1984) (1)
Peritonitis during continuous ambulatory peritoneal dialysis: the role of host defense mechanisms. (1984) (1)
The Obese Zucker Rat Model of Chronic, Progressive Glomerular Injury (1993) (1)
OR-83: Hypertension among osteoarthritis patients treated with rofecoxib, celecoxib, or acetaminophen: an analysis of the data from the pooled VACT studies (2003) (1)
Lipids and Renal Disease (1991) (1)
Effects of Lipid Manipulations in Chronic Renal Failure (1991) (1)
CHAPTER 67 – Management of Hyperlipidemia in Chronic Dialysis Patients (2008) (1)
The Influence of Hemodynamic Factors upon Mesangial Kinetics of Macromolecules (1983) (1)
Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis and Exit-Site Infections: Challenges for the Future (1989) (1)
Cefsulodin pharmacokinetics during hemodialysis. (1982) (1)
Direct effects of altered temperature on renal structure and function. (1988) (1)
Polymorphonuclear leukocyte, T-lymphocyte, and natural killer cell activities in elderly nursing home residents (1986) (1)
DISPOSITION OF MISOPROSTOL AND ITS ACTIVE METABOLITE IN IMPAIRED HEPATIC FUNCTION (1994) (1)
Effects of cyclosporin A, FK-506 and genistein on IL-6, IL-8 production and gene expression by human mononuclear cells (1993) (1)
Tobramycin‐induced hearing loss in a patient with end‐stage renal disease (1983) (1)
Lipids and progressive renal failure. (1996) (1)
Editors JORDAN J. COHEN (1994) (0)
Antibiotics: Vancomycin (1989) (0)
ambulatory peritoneal dialysis fluids. Bacterial growth and killing in chronic (2013) (0)
Diagnostics and techniques. (1996) (0)
Glomerular haemodynamic function in long-term diabetic rats with systemic hypertension (1986) (0)
Effects of Dietary Fatty Acids on Experimental Renal Disease (1993) (0)
Human mononuclear cell proliferation, but not interleukin-6 production, is dependent on isoprenoid products of mevalonate metabolism (1994) (0)
Role of lipid peroxidation in the inhibition of mononuclear cell proliferation by normal I i poproteins (2002) (0)
Relationship between glomerular filtration rate and mesangial kinetics in mercury chloride acute renal failure (1976) (0)
Peritonitis and Other Complications (1998) (0)
THE ROLE OF PROTEINURIA IN THE DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES (2004) (0)
Quiz of the Month, Answer / Publisher’s Note (1984) (0)
Effects of Eicosapentaenoic Acid Plus Docosapentaenoic Acid and Eicosapentaenoic Acid Alone on Fasting and Postprandial Lipids (2016) (0)
Lipids and the Kidney (Preliminary Pages) (1997) (0)
Combined RES stimulation and immunosuppression in glomerular immune complex (IC) injury (1982) (0)
Angiotensin Converting Enzyme Inhibitors and Progressive Renal Insufficiency (2020) (0)
Changing the course of diabetic renal disease by antihypertensive treatment: A meta-regression analysis of published data (1992) (0)
NephrologyDialysis Transplantation Lovastatin inhibits lipopolysaccharide-induced NF-#cB activation in human mesangial cells (2005) (0)
Modulation of renal injury by lipids: Experimental and clinical data (1993) (0)
The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment (2004) (0)
Renal effects of angiotensin converting enzyme inhibitors: Nondiabetic chronic renal disease (2005) (0)
Survival in mercury chloride (HgCl2) induced acute renal failure (ARF) and its relationship to the maintenance of urinary kallikrein excretion (UKE) (1977) (0)
[Hyperlipidemia and nephropathy: cause or consequence?]. (1995) (0)
About the cover illustration: Focal glomerular sclerosis with lipid-filled vacuoles (1997) (0)
The role of lipid abnormalities in renal and vascular injury (1992) (0)
Progression of renal disease : clinical patterns, therapeutic options, and lessons from clinical trials (1997) (0)
[The 32nd Western/Eastern regional meeting, Japanese Society of Nephrology. Wakayama prefecture, Tokyo, Japan. October 4-5, 2002. Abstracts]. (2002) (0)
The renal cardiovascular axis: new diagnostic insights (1997) (0)
P-527: Effect of rofecoxib vs. naproxen on hypertension and edema related events: a multivariate analysis involving 5557 patients from the advantage trial (2002) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William F. Keane?

William F. Keane is affiliated with the following schools: